FROG:NASDAQJFrog Ltd. Analysis
Data as of 2026-06-07 - not real-time
$84.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
JFrog (FROG) is trading well above its 20‑day SMA of 74.35 and the 200‑day SMA of 53.85, with the price at 84 and a bullish MACD crossover (MACD line 8.18 > signal 7.51). The RSI of 69 signals near‑overbought conditions, while volume is trending lower and 30‑day volatility remains elevated at 82.9%, suggesting a short‑term pull‑back risk. The stock’s DCF fair value of 56.66 is well below the current price, yielding a ‑3.9% downside and a forward P/E of 74.8×, indicating that the market is pricing in strong growth but may be overvalued.
Fundamentally, revenue surged 25.8% YoY to $154 M, gross margins stay robust at 77%, and the company generated positive operating cash flow of $155 M and free cash flow of $170 M, backed by $741 M of cash and minimal debt. Recent Q1 2026 results beat expectations, delivering non‑GAAP EPS of $0.27 versus consensus and raising guidance for the next quarter, while analysts have a “strong buy” consensus with a median target of $80, slightly below the current price. The combination of rapid top‑line growth, a cash‑rich balance sheet, and expanding AI/ML pipeline opportunities supports a longer‑term growth narrative, though profitability remains elusive with a negative operating margin of ‑7.4%.
Fundamentally, revenue surged 25.8% YoY to $154 M, gross margins stay robust at 77%, and the company generated positive operating cash flow of $155 M and free cash flow of $170 M, backed by $741 M of cash and minimal debt. Recent Q1 2026 results beat expectations, delivering non‑GAAP EPS of $0.27 versus consensus and raising guidance for the next quarter, while analysts have a “strong buy” consensus with a median target of $80, slightly below the current price. The combination of rapid top‑line growth, a cash‑rich balance sheet, and expanding AI/ML pipeline opportunities supports a longer‑term growth narrative, though profitability remains elusive with a negative operating margin of ‑7.4%.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- RSI near overbought and price approaching resistance
- High short‑term volatility and decreasing volume
- Recent earnings beat but limited margin improvement
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Sustained revenue growth above 25% YoY
- Strong cash generation and low net debt
- Positive guidance and expanding AI/ML product suite
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Strategic positioning in the software supply‑chain market
- Long‑term demand for secure DevSecOps and AI/ML pipelines
- Potential margin expansion as scale drives operating efficiencies
Key Metrics & Analysis
Financial Health
Revenue Growth25.80%
Profit Margin-10.93%
P/E Ratio74.8
ROE-7.14%
ROA-3.73%
Debt/Equity1.78
P/B Ratio11.0
Op. Cash Flow$155.3M
Free Cash Flow$169.9M
Industry P/E32.6
Technical Analysis
TrendBullish
RSI69.1
Support$62.01
Resistance$89.16
MA 20$74.35
MA 50$57.97
MA 200$53.85
MACDBullish
VolumeDecreasing
Fear & Greed Index83.02
Valuation
Fair Value$56.66
Target Price$80.75
Upside/Downside-3.87%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta1.35
Volatility82.91%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.